Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ASPH | Q12797 | 1/20 | 0.31 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132690 | 0.86 | — | — | |
| Water SCHEMBL8567684 | 0.84 | NAPRT (0.32) | NAPRTKDM4EASPHKDM8 | |
| Hydrochloric Acid SCHEMBL1021971 | 0.84 | NAPRT (0.32) | NAPRTKDM4EASPHKDM8 | |
| Hydrochloric Acid SCHEMBL672022 | 0.84 | NAPRT (0.32) | NAPRTKDM4EASPHKDM8 | |
| SCHEMBL9515703 | 0.84 | NAPRT (0.32) | NAPRTKDM4EASPHKDM8 | |
| SCHEMBL30949896 | 0.77 | ALDH1A1 (0.33) | NAPRTALDH1A1HSD17B10TDP1 | |
| SCHEMBL18297654 | 0.71 | ERN1 (0.35) | NAPRTKDM4EALDH1A1TDP1 | |
| Ether SCHEMBL8567683 | 0.71 | HPGD (0.32) | — | |
| SCHEMBL27534125 | 0.69 | CES2 (0.46) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL9150140 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522367-B1 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9107956-B2 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2131865-B1 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140045770-A1 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-02-13 | — | — | US | disclosed |
| US-8598364-B2 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2522367-A1 | Oligomer-protease inhibitor conjugates | Nektar Therapeutics (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110269677-A1 | Oligomer-Protease Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100184989-A1 | De Novo Synthesis of Conjugates | NEKTAR THERAPEUTICS (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2131865-A2 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | Nektar Therapeutics (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-2125027-A2 | DE NOVO SYNTHESIS OF CONJUGATES | Nektar Therapeutics (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008112286-A9 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS AL CORP (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008112286-A2 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112289-A2 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184989-A1 | De Novo Synthesis of Conjugates | ABCG2, UGT1A8, SLC7A5 | NAPRT 577/4885KDM4E 4261/4885ASPH 616/4885 |
| US-20140045770-A1 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | DNPEP, ADAM17, SERPINB1 | NAPRT 1842/4885KDM4E 4073/4885ASPH 328/4885 |
| US-20110269677-A1 | Oligomer-Protease Inhibitor Conjugates | ADAM17, DNPEP, SERPINB1 | NAPRT 2237/4885KDM4E 4064/4885ASPH 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.